Inotek Pharmaceuticals Announces Participation at Upcoming Investor Conferences
September 06 2016 - 7:00AM
Business Wire
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of therapies for ocular diseases,
today announced that David P. Southwell, President and Chief
Executive Officer, and Claudine Prowse, PhD, Vice President,
Strategy and IRO, are scheduled to participate at the following
investor conferences:
- Rodman & Renshaw 18th Annual Global
Investment Conference on September 13, 2016 in New York City
- Mizuho Securities Therapeutics
Conference on September 21, 2016 in Boston, MA
About Inotek Pharmaceuticals Corporation
Inotek Pharmaceuticals is a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of therapies for glaucoma and other eye diseases.
The Company’s lead product candidate, trabodenoson, is a
first-in-class selective adenosine mimetic currently in Phase 3
development. Trabodenoson was developed in Inotek’s
laboratories and is designed to restore the eye’s natural pressure
control mechanism. Additionally, the Company is evaluating the
potential for selective adenosine mimetics to address optic
neuropathies and other degenerative retinal diseases. For more
information, please visit www.inotekpharma.com. The inclusion of
our website address here and elsewhere in this press release does
not include or incorporate by reference the information on our
website into this press release.
Forward-Looking Statements
This press release contains forward-looking statements, which
are subject to substantial risks, uncertainties and assumptions.
You should not place reliance on these statements often include
words such as "believe," "expect," "anticipate," "intend," "plan,"
"estimate," "seek," "will," "may" or similar expressions. Although
the Company believes that the expectations reflected in the
forward-looking statements are reasonable, the Company cannot
guarantee such outcomes. Accordingly, you should not place undue
reliance on these forward-looking statements. All such statements
speak only as of the date made, and the Company undertakes no
obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160906005184/en/
Inotek Contact:Claudine Prowse, PhD, 781-552-4305Vice
President, Strategy and IROIR@inotekpharma.comorInvestor
Contact:MacDougall Biomedical CommunicationsChris Erdman,
781-235-3060cerdman@macbiocom.comorMedia Contact:MacDougall
Biomedical CommunicationsKaren Sharma,
781-235-3060ksharma@macbiocom.com
INOTEK PHARMACEUTICALS CORP (NASDAQ:ITEK)
Historical Stock Chart
From Mar 2024 to Apr 2024
INOTEK PHARMACEUTICALS CORP (NASDAQ:ITEK)
Historical Stock Chart
From Apr 2023 to Apr 2024